M. Catherine Pietanza, MD, on A Promising New Agent for SCLC
2015 European Cancer CongressM. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).
Related Videos
Martine J. Piccart-Gebhart, MD, PhD, on Reducing the Cost and Increasing Access to Cancer Drugs
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Matti S. Aapro, MD, on Geriatric Oncology: A Multidisciplinary Approach for Positive Outcomes
Matti S. Aapro, MD, of IMO Clinique de Genolier, offered a case presentation and a cross-disciplinary approach to finding the best way to effect a cure with minimal impact on quali...
Mary K. Gospodarowicz, MD, on Challenges in Cancer Control
Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital ...
Rolf A. Stahel, MD, on Results From the BELIEF Trial
Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung ...
Milena Sant, MD, on The Latest Findings From the EUROCARE 5 Study
Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).
